Forte Biosciences Files 8-K Report
Ticker: FBRX · Form: 8-K · Filed: May 13, 2024 · CIK: 1419041
Sentiment: neutral
Topics: corporate-filing, financials
TL;DR
Forte Biosciences dropped an 8-K on May 13th covering financials and other key events.
AI Summary
On May 13, 2024, Forte Biosciences, Inc. filed an 8-K report detailing significant corporate events. The filing includes information on the company's results of operations and financial condition, as well as other events and financial statements. Forte Biosciences, Inc. is incorporated in Delaware and its principal executive offices are located in Dallas, Texas.
Why It Matters
This 8-K filing provides an update on Forte Biosciences' financial condition and operational events, which is crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard corporate disclosure and does not appear to contain any immediate negative news or significant risk factors.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- May 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Dallas, Texas (location) — Principal Executive Offices
- 3060 Pegasus Park Drive, Building 6 (address) — Principal Executive Offices Address
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details of the financial condition are not provided in the excerpt.
What are the 'Other Events' mentioned in the filing?
The filing lists 'Other Events' as an item information, but the specific nature of these events is not detailed in the provided text.
When was Forte Biosciences, Inc. incorporated?
Forte Biosciences, Inc. was incorporated in Delaware.
What is the business address of Forte Biosciences, Inc.?
The business address is 3060 Pegasus Park Drive, Building 6, Dallas, Texas, 75247.
Does this filing mention any former company names?
Yes, the filing notes that the former company name was Tocagen Inc., with a date of name change on 20071120.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-05-13 16:06:09
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d825808d8k.htm (8-K) — 25KB
- d825808dex991.htm (EX-99.1) — 43KB
- d825808dex992.htm (EX-99.2) — 27KB
- g825808ex99_2p10g1.jpg (GRAPHIC) — 230KB
- g825808ex99_2p11g1.jpg (GRAPHIC) — 223KB
- g825808ex99_2p12g1.jpg (GRAPHIC) — 63KB
- g825808ex99_2p13g1.jpg (GRAPHIC) — 410KB
- g825808ex99_2p14g1.jpg (GRAPHIC) — 325KB
- g825808ex99_2p15g1.jpg (GRAPHIC) — 196KB
- g825808ex99_2p16g1.jpg (GRAPHIC) — 66KB
- g825808ex99_2p17g1.jpg (GRAPHIC) — 158KB
- g825808ex99_2p18g1.jpg (GRAPHIC) — 143KB
- g825808ex99_2p19g1.jpg (GRAPHIC) — 191KB
- g825808ex99_2p1g1.jpg (GRAPHIC) — 101KB
- g825808ex99_2p20g1.jpg (GRAPHIC) — 187KB
- g825808ex99_2p21g1.jpg (GRAPHIC) — 202KB
- g825808ex99_2p22g1.jpg (GRAPHIC) — 192KB
- g825808ex99_2p23g1.jpg (GRAPHIC) — 41KB
- g825808ex99_2p24g1.jpg (GRAPHIC) — 119KB
- g825808ex99_2p25g1.jpg (GRAPHIC) — 172KB
- g825808ex99_2p26g1.jpg (GRAPHIC) — 220KB
- g825808ex99_2p27g1.jpg (GRAPHIC) — 216KB
- g825808ex99_2p28g1.jpg (GRAPHIC) — 138KB
- g825808ex99_2p29g1.jpg (GRAPHIC) — 167KB
- g825808ex99_2p2g1.jpg (GRAPHIC) — 559KB
- g825808ex99_2p30g1.jpg (GRAPHIC) — 174KB
- g825808ex99_2p31g1.jpg (GRAPHIC) — 313KB
- g825808ex99_2p32g1.jpg (GRAPHIC) — 257KB
- g825808ex99_2p3g1.jpg (GRAPHIC) — 269KB
- g825808ex99_2p4g1.jpg (GRAPHIC) — 284KB
- g825808ex99_2p5g1.jpg (GRAPHIC) — 57KB
- g825808ex99_2p6g1.jpg (GRAPHIC) — 257KB
- g825808ex99_2p7g1.jpg (GRAPHIC) — 87KB
- g825808ex99_2p8g1.jpg (GRAPHIC) — 281KB
- g825808ex99_2p9g1.jpg (GRAPHIC) — 232KB
- g825808g04m98.jpg (GRAPHIC) — 6KB
- 0001193125-24-137210.txt ( ) — 9237KB
- fbrx-20240513.xsd (EX-101.SCH) — 3KB
- fbrx-20240513_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240513_pre.xml (EX-101.PRE) — 11KB
- d825808d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: May 13, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer